INBX vs. ADMA, BEAM, NMRA, TWST, FUSN, RXRX, DNA, SANA, FDMT, and KYMR
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include ADMA Biologics (ADMA), Beam Therapeutics (BEAM), Neumora Therapeutics (NMRA), Twist Bioscience (TWST), Fusion Pharmaceuticals (FUSN), Recursion Pharmaceuticals (RXRX), Ginkgo Bioworks (DNA), Sana Biotechnology (SANA), 4D Molecular Therapeutics (FDMT), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
ADMA Biologics (NASDAQ:ADMA) and Inhibrx (NASDAQ:INBX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by insiders. Comparatively, 22.2% of Inhibrx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ADMA Biologics has higher revenue and earnings than Inhibrx. ADMA Biologics is trading at a lower price-to-earnings ratio than Inhibrx, indicating that it is currently the more affordable of the two stocks.
ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500.
ADMA Biologics received 374 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 71.68% of users gave ADMA Biologics an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
ADMA Biologics has a net margin of -1.29% compared to ADMA Biologics' net margin of -13,408.95%. Inhibrx's return on equity of 17.51% beat ADMA Biologics' return on equity.
ADMA Biologics presently has a consensus price target of $10.50, suggesting a potential upside of 19.18%. Inhibrx has a consensus price target of $27.00, suggesting a potential downside of 21.26%. Given Inhibrx's stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Inhibrx.
In the previous week, ADMA Biologics had 29 more articles in the media than Inhibrx. MarketBeat recorded 34 mentions for ADMA Biologics and 5 mentions for Inhibrx. Inhibrx's average media sentiment score of 0.60 beat ADMA Biologics' score of 0.47 indicating that ADMA Biologics is being referred to more favorably in the media.
Summary
ADMA Biologics beats Inhibrx on 14 of the 19 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
